Due Diligence

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...

Challenge: A European investor required due diligence support to appraise the attractiveness of a series of potential investments. The technologies included a theranostic agent, a DNA damage response...

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...

Challenge: An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The...

Challenge: Our client was a pharmaceutical company considering an acquisition of two approved assets and required expert due diligence on the clinical, regulatory and manufacturing aspects of the two...

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...